The FLONASE®

Brand Family

The FLONASE® Brand Family

The FLONASE® Brand Family offers three products to fit
your patients’ various needs.


The FLONASE® Brand Family MOA

The FLONASE® Brand Family does more to block the allergic cascade*

The FLONASE® Brand Family works to help block 6 key inflammatory mediators, not just histamine†20-23:

  • Histamine
  • Cytokines
  • Leukotrienes
  • Chemokines
  • Prostaglandins
  • Tryptases

The allergic cascade involves more than just histamine

The body’s immune response to allergens includes a series of early- and late-phase reactions—the allergic cascade.24 While a number of allergic mediators are involved in this cascade, single-ingredient, oral, nonsedating antihistamines (NSAs) block only histamine.20,23

While single-ingredient oral NSAs are absorbed systemically before they can act on the nasal mucosa, FLONASE® Brand products are delivered locally, act directly in the nasal passage, and relieve nasal congestion; single-ingredient NSAs do not.20-23 In addition, FLONASE® Brand products are the only OTC intranasal corticosteroids (INS)indicated to relieve nasal allergy symptoms and itchy, watery eyes.§25-29

Mechanism vs most allergy pills. FLONASE® acts on multiple inflammatory mediators (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

THE FLONASE® OCULAR INDICATION

The FLONASE® Brand Family of products—the only OTC INS products indicated to treat ocular
symptoms such as itchy, watery eyes.25-29

FLONASE® Allergy Relief—same nasal allergy relief trusted for more than 20 years—with an ocular indication.1-13, 30

FLONASE® Allergy Relief ocular data

FLONASE® SENSIMIST™ Allergy Relief—proven to relieve seasonal ocular allergy symptoms4,14-17,31

FLONASE® SENSIMIST™ Allergy Relief Ocular Data

§Ocular symptom relief indicated for patients aged 12 and older.

 

WHICH PRODUCT

IS RIGHT FOR

MY PATIENT?

Explore different patient types 

and find out which product is 

right for your patients

References

1. IMS Health Incorporated. IMS National Prescription Audit MAT (October 2010-September 2016) 2. Greiner AN, Hellings PW, Rotiroti G, Scadding  GK. Allergic rhinitis. Lancet. 2011;378(9809):2112-2122. 3. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):S1-S84. 4. Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy. 1991;67(3):332-338. 5. Banov CH, Woehler TR, LaForce CF, Pearlman DS, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy. 1994;73(3):240-246. 6. Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol. 2003;91(1):44-48.  7. Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy. 1995;25(8): 737-743. 8. Van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol. 1993;91(6):1146-1154. 9. GlaxoSmithKline. A multicenter, randomized, double-blind, parallel-group study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis. https://www.gsk-clinicalstudyregister.com/files2/1197.pdf. Updated December 19, 2005. Accessed November 2, 2016. 10. Ratner PH, Howland WC III, Jacobs RL, et al. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc. 2002;23(4):259-263. 11. Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology. 1993;31(4):169-174. 12. Bernstein DI, Levy AL, Hampel FC, et al. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(6):952-957. 13. DeWester J, Philpot EE, Westlund RE, Cook CK, Richard KA. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):331-337. 14. Avamys [product monograph]. Mississauga, Canada: GlaxoSmithKline Inc; 2015. 15. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(6):1430-1437. 16. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007;62(9):1078-1084. 17. Jacobs R, Martin B, Hampel F, Toler W, Ellsworth A, Philpot E. Effectiveness of fluticasone furoate 110 µg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin. 2009;25(6):1393-1401. 18. GlaxoSmithKline. A randomized, double-blind, placebo-controlled, parallel-group, multicenter, study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg for 4 weeks in adult and adolescent subjects (≥12 years of age) with perennial allergic rhinitis (PAR). https://www.gsk-clinicalstudyregister.com/files2/20736.pdf. Updated March 6, 2008. Accessed November 2, 2016. 19. Data on file, GlaxoSmithKline. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg for 14 days in adult and adolescent subjects with seasonal allergic rhinitis. https://www.gsk-clinicalstudyregister.com/files2/20737.pdf. Updated March 6, 2008. Accessed November 2, 2016. 20. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-1300. 21. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol. 2004;114(5 Suppl):S135-S138. 22. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol. 1992;90(4 Pt 2):699-704. 23. Bachert C, Geveart P. Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy. 1999;54(Suppl 57):116-123. 24. IgE’s role in allergic asthma. Coping with Allergies & Asthma Website. http://copingmag.com/ana/index.php/feature_article/iges_role_in_allergic_asthma. Accessed November 4, 2016. Originally published in Coping® with Allergies & Asthma Magazine, Spring/Summer 2011. 25. FLONASE® Drug Facts Label. 26. FLONASE® SENSIMIST™ Drug Facts Label. 27. NASACORT Drug Facts Label. 28. RHINOCORT Drug Facts Label. 29. CLARISPRAY Drug Facts Label. 30. Meltzer EO, Orgel HA, Bronsky EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol. 1990;86(2):221-230. 31. Vasar M, Houle P-A, Douglass JA, et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3):313-321.